MSD’s monoclonal antibody, indicated for 15 types of cancer, smashed industry records with sales of $27.3 billion in 2024, ...

Recent market volatility notwithstanding, equities generally deliver solid returns over long periods, like a decade. The key ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.

Merck dazzled with Phase 3 trial results for its PAH drug WINREVAIR, but the market responded with a collective shrug, ...

Merck’s latest clinical data puts a shiny new needle on its cancer blockbuster Keytruda, showing that a quick two-minute ...

The health sector faces challenges as Novo Nordisk's sales projections dim, Johnson & Johnson's unit faces hefty fines, and ...

Despite the broader market downturn, 10 individual stocks showed a strong performance during the trading session, with three ...

MSD's new injectable Keytruda formulation offers similar effectiveness to the intravenous version, potentially halving ...

Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or ...

BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...

Merck has shared data from the pivotal Phase 3 trial evaluating the subcutaneous administration of pembrolizumab together ...